Table 1.
Characteristics of studies included in the meta-analysis
| Author | Year | Region | Type of cancer | Sample size (high/low) | Follow-up (month) | Endpoints | Expression associated with poor prognosis | Samples detected | Assay method | Cut-off value | Survival analysis | NOS score | Method |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lee et al. | 2018 | Korea | Biliary tract cancer | 4/23 | 23 | OS | High | Blood | ELISA | High: serum CXCL5 levels were > 2.081 ng/mL | Multivariate | 7 | 1 |
| Bièche et al. | 2007 | France | Breast cancer | 24/24 | 120 | RFS | High | Tissue | RT-PCR | ROC | Univariate | 7 | 2 |
| Oksana et al. | 2014 | Poland | Lung cancer | 37/37 | 82 | OS, DFS | Low | Tissue | RT-PCR | High: the gene expression of CXCL5 in tumor tissue was more than 1.08 times than normal tissue | Multivariate | 7 | 2 |
| Zhou et al. | 2014 | China | Intrahepatic cholangiocarcinoma | 70/70 | 120 | OS | High | Tissue | IHC | Median | Univariate Multivariate | 7 | 1 |
| Zhu et al. | 2016 | China | Bladder cancer | 131/124 | 87 | OS, RFS, PFS | High | Tissue | IHC | High: IRS > 4 | NA | 7 | 2 |
| Dai et al. | 2016 | China | Glioma | 34/31 | 48 | OS | High | Tissue | WB, RT-PCR | Median | NA | 6 | 2 |
| Wu et al. | 2017 | China | Lung cancer | 75 | 60 | OS | High | Tissue | IHC,RT-PCR | High: the multiplication for intensity and proportion was more than 2 | Univariate Multivariate | 7 | 2 |
| 2437 | 60 | OS, PFS | High | Tissue | RT-PCR | Median | Univariate | 6 | 1 | ||||
| Kawamura et al. | 2011 | Japan | Colorectal cancer | 69/181 | 104 | OS | High | Blood | ELISA | High: serum CXCL5 levels were > 1.53 ng/mL | Univariate Multivariate | 7 | 1 |
| Han et al. | 2015 | China | Lung adenocarcinoma | 34/192 | 127 | OS,RFS | High | Tissue | RT-PCR | Median | Univariate | 6 | 2 |
| Speetjens et al. | 2008 | The Netherlands | Colorectal cancer | Cohort 1 53/17 | 172 | DFS | Low | Tissue | RT-PCR | The 25th percentile as cut off point | Univariate Multivariate | 7 | 1 |
| Cohort 2 50/8 | 162 | OS | Low | Tissue | IHC | High: CXCL5 expression in > 50% of the tumor cells | Univariate Multivariate | 7 | 1 | ||||
| Okabe et al. | 2012 | Japan | Intrahepatic cholangiocarcinoma | 25/25 | 126.3 | OS | High | Tissue | IHC | High: a percentage of the total number of stained cells > 10% | NA | 6 | 2 |
| Li et al. | 2010 | USA | Pancreatic cancer | 130/23 | 180 | OS | High | Tissue | IHC | High: percentage of tumor cells staining positively for CXCL5 > 5.5% | NA | 6 | 2 |
| Zhou et al. | 2012 | China | Hepatocellular carcinoma | 47/47 | 50 | OS | High | Tissue | IHC | Median | Univariate Multivariate | 8 | 1 |
| 162/161 | 75 | OS | High | Tissue | IHC | Median | Univariate Multivariate | 8 | 1 | ||||
| 251/251 | 75 | OS | High | Tissue | IHC | Median | Univariate Multivariate | 8 | 1 | ||||
| Zhang et al. | 2013 | China | Nasopharyngeal carcinoma | 75/70 | 105 | OS, PFS | High | ELISA | High: serum CXCL5 levels were > 0.805 ng/ml | Univariate Multivariate | 7 | 1 | |
| Zhao et al. | 2017 | China | Colorectal cancer | 48/30 | 60 | OS, DFS | High | IHC | High: a staining score of 4.5 as the cut-off value | Univariate Multivariate | 8 | 1 |
Method: 1 denoted as obtaining HRs directly from publications; 2 denoted as HRs calculated from the total number of events, corresponding p value and data from Kaplan–Meier curves
OS overall survival, DFS disease-free survival, PFS progression-free survival, RFS recurrence-free survival, IHC immunohistochemistry, RT-PCR real time polymerase chain reaction, ELISA enzyme-linked immunosorbent assay, NA not available, ROC receiver operating characteristics, NOS Newcastle–Ottawa Scale